This South Yorkshire firm brings together leaders in biopharmaceuticals and facilitates meetings that seek to solve industry challenges and improve best practice. It covers areas such as the manufacture and supply of drugs, and has signed up 24 of the 25 largest firms as clients, including Bayer, Glaxo Smith Kline and Astra Zeneca. Sales, which represent subscription fees from more than 70 member groups, hit £5.2m last year. All its sales originated overseas. The firm is led by Simon Chalk, 57, and sold a minority stake to the private equity firm Vespa Capital for an undisclosed sum in June. It has begun to expand into the cell and gene therapy industry.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.